Chest CT scans to predict lung disease in scleroderma
Part of Skin clinical trials.
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with systemic sclerosis (scleroderma).
- You must be 18 years old or older.
- You must have had a high-resolution CT scan of your chest taken between January 1, 1990 and December 31, 2019.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles in your blood to see if they can predict whether you might develop a serious lung condition called pulmonary arterial hypertension (high blood pressure in the lungs). It aims to find better ways to detect and manage this complication early.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study looks at people aged 18 and older who have a connective tissue disease and lung involvement. It aims to better understand how these lung problems progress and may help doctors choose better care.
This study checks if a computer program can reliably measure the amount of lung scarring on chest CT scans. It's for people with certain types of interstitial lung disease who are already scheduled for a routine CT scan.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.